Today, The Francis Crick Institute signed an agreement giving Axol Bioscience exclusive rights to a methodology to generate human pluripotent stem cell (hPSC) derived cells used in drug screening and cardiotoxicity assays.
The technology developed by the Crick is used to generate near-homogeneous populations of hPSC derived left ventricular cardiomyocytes (LVCMs) with improved structural, functional and metabolic maturity. The initial discovery was protected, funded and further developed towards commercial application in-house at the Crick. This work has just been published in Cell Reports Methods and the intellectual property has been licensed to Axol Bioscience for both the production and supply of LVCMs, as well as the provision of screening services. [Read more…]